Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;67(8):923-30.
doi: 10.1001/archneurol.2010.161.

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Clemens Warnke  1 , Til Menge, Hans-Peter Hartung, Michael K Racke, Petra D Cravens, Jeffrey L Bennett, Elliot M Frohman, Benjamin M Greenberg, Scott S Zamvil, Ralf Gold, Bernhard Hemmer, Bernd C Kieseier, Olaf Stüve
Affiliations
Review

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Clemens Warnke et al. Arch Neurol. 2010 Aug.

Abstract

Natalizumab (Tysabri) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, 3 patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with progressive multifocal leukoencephalopathy (PML). The agent was later reapproved and its use restricted to monotherapy in patients with relapsing forms of MS. Since reapproval in 2006, additional cases of PML were reported in patients with MS receiving natalizumab monotherapy. Thus, there is currently no convincing evidence that natalizumab-associated PML is restricted to combination therapy with other disease-modifying or immunosuppressive agents. In addition, recent data indicate that risk of PML might increase beyond 24 months of treatment.

PubMed Disclaimer

References

    1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–31. - PubMed
    1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992;10:153–87. - PubMed
    1. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47(6):707–17. - PubMed
    1. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210–8. - PMC - PubMed
    1. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6(12):1182–90. - PubMed

MeSH terms